Abbott Laboratories, with CEO Robert B. Ford, is a global healthcare company engaged in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The company played a major role in COVID-19 testing with its rapid diagnostics kits. Under Ford, Abbott has focused on expanding its medical device portfolio, including the Freestyle Libre glucose monitoring system. It also maintains strong global nutrition brands like Ensure and Pedialyte. Abbott is recognized for advancing consumer health and diagnostics.
Abbott combines medical devices, diagnostics and nutrition, giving it a comparatively defensive earnings base. Continuous glucose monitoring remains an attractive structural growth driver, while routine diagnostics and established products provide balance. Formula-related litigation and product quality issues remain important risks that deserve a valuation reserve. A recession should have limited impact on essential care, although elective procedures and emerging-market currencies can soften. Current growth forecasts are healthy but not exceptional.

Senior Financial Analyst
Experienced financial analyst specializing in company ratings and sector performance. Delivers in-depth evaluations of financial health, growth potential, and risk exposure to support investment decisions. Skilled in ratio analysis, forecasting, and market benchmarking.
9 years of experience
This interactive tool helps you determine whether this stock fits into your investment strategy based on your portfolio size, risk tolerance, and allocation preferences.
A 26.6 P/E ratio indicates this stock trades at a premium valuation. With a Medium risk rating, this stock may suit moderate risk tolerance.
⚠️ This tool is for informational purposes only. It does not constitute financial advice. Investing involves risk, including loss of capital. Always consult a licensed financial advisor before making investment decisions.